Q-omics provides the consensus-scored HTRA2 profile across patient tissues and cancer cell-line models. HTRA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HTRA2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HTRA2 RNA expression shows 19,093 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where HTRA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTRA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTRA2 survival associations across molecular data types. HTRA2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTRA2 RNA expression–survival associations across cancer types. High HTRA2 expression shows unfavorable associations in ACC, LIHC, KICH, MESO and BLCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HTRA2 RNA expression.
This table summarizes HTRA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HTRA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTRA2 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRC, LIHC and COAD. The HNSC box plot shows higher HTRA2 RNA expression in tumor versus normal tissue (log2 FC = +0.950, t-test p < 0.001).
This table shows molecular features associated with HTRA2 in patient tissues and cancer cell lines. In patient samples, HTRA2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HTRA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
